Phase 3 CLL/SLL trial of ICP-248 plus orelabrutinib doses first patient
The first patient has been dosed in a Phase 3 clinical trial testing ICP-248 (mesutoclax) in combination with orelabrutinib in adults with chronic lymphocytic leukemia…
The first patient has been dosed in a Phase 3 clinical trial testing ICP-248 (mesutoclax) in combination with orelabrutinib in adults with chronic lymphocytic leukemia…
The U.S. Food and Drug Administration (FDA) has granted its approval to the oral medication Cabometyx (cabozantinib) as a treatment for certain types of…
Combining VXM01, an experimental anticancer vaccine, with Bavencio (avelumab), which activates the immune system to attack cancer cells, was well tolerated in a…
Interim data from a Phase 3 trial failed to show that a combination of nemvaleukin, an experimental immune-modulating therapy, and Keytruda (pembrolizumab) could outperform standard…
A personalized cancer vaccine called PGV001 showed potential in combating several types of cancer, both solid tumors and blood malignancies like myeloma, in a…
Treatment with the experimental cancer vaccine OSE2101, given in combination with standard chemotherapy, led to positive early results in a Phase 2 clinical trial…
A European Medicines Agency (EMA) committee recommended that Jaypirca (pirtobrutinib) be approved to treat some adult patients with chronic lymphocytic leukemia (CLL), a type of…
Treatment with CAN-2409, an immune-modulating anticancer therapy, showed promising trends toward improved survival in a Phase 2 clinical trial involving people with pancreatic cancer,…
The presence of more than one high-risk genetic abnormality is associated with dramatically more aggressive multiple myeloma, a study reported. Its findings highlight the…
Aptose Biosciences will be testing a higher dose of tuspetinib as part of a triple-combination regimen that’s being explored in a clinical trial…